Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma Academic Article uri icon


MeSH Major

  • Antimetabolites, Antineoplastic
  • Azacitidine
  • Forkhead Transcription Factors
  • Leukemia, Myeloid, Acute


  • The blockade of immunological checkpoints has been successfully employed for the treatment of various solid neoplasms including melanoma, mesothelioma, non-small cell lung carcinoma, and renal cell carcinoma. A recent study indicates that the vast majority of patients with advanced, heavily pretreated Hodgkin's lymphoma (HL) also respond to a monoclonal antibody targeting programmed cell death 1 (PDCD1, best known as PD-1). Thus, checkpoint blockers may soon become part of our therapeutic armamentarium against hematological tumors. This would be particularly important as it would spare (at least some) patients the deleterious toxic effects of combinatorial chemotherapies and bone marrow transplantation. We anticipate that the realm of immunotherapy will eventually conquer vast portions of the territory that now belongs to hematological malignancies.

publication date

  • January 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC4485757

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2015.1008853

PubMed ID

  • 26155425

Additional Document Info

start page

  • e1008853


  • 4


  • 6